National Health (Price and Special Patient Contribution) Amendment Determination 2017 (No. 5) (PB 56 of 2017) (Cth)
PB 56 of 2017
National Health (Price and Special Patient Contribution) Amendment Determination 2017 (No. 5)
National Health Act 1953
I, PENNY SHAKESPEARE, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.
Dated 21 July 2017
PENNY SHAKESPEARE
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
1 Name of Instrument
(1) This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2017 (No. 5).
(2) This Instrument may also be cited as PB 56 of 2017.
2 Commencement
This Instrument commences on 1 August 2017.
3 Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)
Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).
Schedule 1 Amendments
[1]Schedule 1, entry for Amlodipine in the form Tablet 5 mg (as besylate)
omit from the column headed “Claimed Price”: 7.55 substitute: 9.38
[2] Schedule 1, entry for Amlodipine in the form Tablet 10 mg (as besylate)
omit from the column headed “Claimed Price”: 8.23 substitute: 10.03
[3] Schedule 1, entry for Clindamycin
omit from the column headed “Claimed Price”: 12.50 substitute: 14.39
[4]Schedule 1, entry for Donepezil in each of the forms: Tablet containing donepezil hydrochloride 5 mg; and Tablet containing donepezil hydrochloride 10 mg
omit from the column headed “Claimed Price”: 16.21 substitute: 15.63
[5] Schedule 1, entry for Doxepin in the form Capsule 10 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 8.27 substitute: 9.20
[6] Schedule 1, entry for Doxepin in the form Capsule 25 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 8.37 substitute: 9.30
[7] Schedule 1, entry for Exemestane
omit from the column headed “Claimed Price”: 54.10 substitute: 55.34
[8] Schedule 1, entry for Glipizide
omit from the column headed “Claimed Price”: 13.78 substitute: 14.25
[9] Schedule 1, entry for Indapamide
insert as first item in the columns in the order indicated:
| Tablet containing indapamide hemihydrate 1.5 mg | Oral | Natrilix SR | 90 | 8.10 | 12.70 |
Schedule 1, entry for Lansoprazole in the form Tablet 15 mg (orally disintegrating)
omit from the column headed “Claimed Price”: 7.74 substitute: 7.98
Schedule 1, entry for Lansoprazole in the form Tablet 30 mg (orally disintegrating)
omit from the column headed “Claimed Price”: 10.53 substitute: 10.79
Schedule 1, entry for Levonorgestrel with Ethinyloestradiol in the form Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets [Brand: Nordette 28]
omit from the column headed “Claimed Price”: 17.32 substitute: 18.48
Schedule 1, entry for Levonorgestrel with Ethinyloestradiol in the form Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets [Brand: Triphasil 28]
omit from the column headed “Claimed Price”: 18.81 substitute: 19.27
Schedule 1, entry for Medroxyprogesterone in the form Injection containing medroxyprogesterone acetate 150 mg in 1 mL
omit from the column headed “Claimed Price”: 18.72 substitute: 19.65
Schedule 1, entry for Medroxyprogesterone in the form Tablet containing medroxyprogesterone acetate 5 mg
omit from the column headed “Claimed Price”: 13.21 substitute: 13.67
Schedule 1, entry for Medroxyprogesterone in the form Tablet containing medroxyprogesterone acetate 10 mg [Pricing Quantity/Pack Quantity: 30]
omit from the column headed “Claimed Price”: 12.16 substitute: 12.62
Schedule 1, entry for Medroxyprogesterone in the form Tablet containing medroxyprogesterone acetate 10 mg [Pricing Quantity/Pack Quantity: 100]
omit from the column headed “Claimed Price”: 27.06 substitute: 27.53
Schedule 1, entry for Moclobemide in the form Tablet 150 mg
omit from the column headed “Claimed Price”: 9.36 substitute: 11.85
Schedule 1, entry for Moclobemide in the form Tablet 300 mg
omit from the column headed “Claimed Price”: 15.73 substitute: 17.92
Schedule 1, entry for Piroxicam in the form Capsule 10 mg
omit from the column headed “Claimed Price”: 11.19 substitute: 12.12
Schedule 1, entry for Piroxicam in each of the forms: Capsule 20 mg; and Dispersible tablet 20 mg
omit from the column headed “Claimed Price”: 10.96 substitute: 11.89
Schedule 1, entry for Quinapril in the form Tablet 5 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 6.35 substitute: 6.82
Schedule 1, entry for Quinapril in the form Tablet 10 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 6.78 substitute: 7.62
Schedule 1, entry for Quinapril in the form Tablet 20 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 7.65 substitute: 8.48
Schedule 1, entry for Sertraline in each of the forms: Tablet 50 mg (as hydrochloride); and Tablet 100 mg (as hydrochloride)
omit from the column headed “Claimed Price”: 5.71 substitute: 6.97
Schedule 1, entry for Spironolactone in the form Tablet 25 mg
omit from the column headed “Claimed Price”: 10.71 substitute: 11.64
Schedule 1, entry for Spironolactone in the form Tablet 100 mg
omit from the column headed “Claimed Price”: 24.40 substitute: 25.33
Schedule 1, entry for Sulfasalazine
omit from the column headed “Claimed Price”: 21.77 substitute: 22.01
Schedule 1, omit entry for Timolol
Schedule 1, entry for Trandolapril in the form Capsule 500 micrograms
(a) omit from the column headed “Determined Price”: 1.39 substitute: 1.96
(b) omit from the column headed “Claimed Price”: 4.64 substitute: 5.22
0
0
0